The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

Urology

Volumn 47, Issue 2, 1996, Pages 169-178

  Hillman, Alan L ^a   Schwartz, J Sanford ^b   Willian, Mary Kaye ^b   Peskin, Ellen ^b   Roehrborn, Claus G ^b   Oesterling, Joseph E ^b   Mason, Michael F ^b   Maurath, Clem J ^b   Deverka, Patricia A ^b   Padley, Robert J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TERAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COST-BENEFIT ANALYSIS; DIAGNOSIS-RELATED GROUPS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; REGRESSION ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 9044236517     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80410-5     Document Type: Article

References (26)

1. Goluboff ET, and Olsson CA: Urologists on a tightrope: coping with a changing economy. J Urol 151: 1-4, 1994.
2. Berry SJ, Coffey DS, Walsh PC, and Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479, 1984.
3. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, and Lieber MM: New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 155: 477-481, 1995.
4. Glynn RJ, Campion EW, Bouchard GR, and Silbert JE: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 121: 78-90, 1985.
5. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE, and Lieber MM: Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44: 825-831, 1994.
6. Garraway WM, and Kirby RS: Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions. Urology 44: 629-636, 1994.
7. Barry MJ: Medical outcomes research and benign prostatic hyperplasia. Prostate: 3 (suppl): 61-74, 1990.
8. Barry MJ: Mulley AG Jr, Fowler FJ, and Wennberg JW: Watchful waiting vs. immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. JAMA 259: 3010-3017, 1988.
9. Fowler FJ Jr, Wennberg JE, Timothy RP, Barry MJ, Mulley AG Jr, and Hanley D: Symptom status and quality of life following prostatectomy. JAMA 259: 3018-3022, 1988.
10. Oesterling JE: Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 332: 99-109, 1995.
11. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, and Proctor C: Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 141: 248-253, 1989.
12. Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, Cohen MM, and Ramsey E: Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 320: 1120-1124, 1989.
13. McConnell JD, Barry MJ, and Bruskewitz RC: Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research, Clin Pract Guide/Quick Ref Guide Clin (Feb) 1-17, 1994.
14. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, and Henderson WG: A comparison transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 332: 75-79, 1995.
15. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 45: 406-413, 1995.
16. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, and Cockett AT: The American Urological Association symptom index for benign prostatic hyperplasia. The Mesurement Committee of the American Urological Association. J Urol 148: 1549-1557, 1992.
17. Roehrborn C, Oesterling JO, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, and Padley RJ: The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in treatment of men with symptomatic benign prostatic hyperplasia. Urology 47: 159-168, 1996.
18. Varga J, and Jiminez SA: Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders. Review. Ann Intern Med 122: 60-62, 1995.
19. Revicki DA, Irwin D, Reblando J, and Simon GE: The accuracy of self-reported disability days. Med Care 32: 401-404, 1994.
20. Yaffe R, Shapiro S, Fuchsberg RR, Rohde CA, and Corpeno HC: Medical economics survey-methods study: cost-effectiveness of alternative survey strategies. Med Care 16: 641-659, 1978.
21. Topol EJ, Ellis SG, Cosgrove DM, Bates ER, Muller DW, Schork NJ, Schork MA, and Loop FD: Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation 87: 1489-1497, 1993.
22. Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyak MJ, O'Leary MP, and Painter MR: Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 154: 205-206, 1995.
23. Weis KA, Epstein RS, Huse DM, Deverka DA, and Oster G: The costs of prostatectomy for benign prostatic hyperplasia. Prostate 22: 325-334, 1993.
24. Lowe F, McDaniel R, Chmiel J, and Hillman A: Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 46: 477-483, 1995.
25. Ball AJ, Feneley RC, and Abrams PH: The natural history of untreated "prostatism." Br J Urol 53: 613-616, 1981.
26. Birkhoff JD, Wiederhorn AR, Hamilton ML, and Zinsser HH: Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 7: 48-52, 1976.